Biocon gets USFDA EIR with VAI Classification for its Malaysian Insulin Manufacturing Facility Medical Dialogues Bureau1 April 2020 12:44 PM ISTBengaluru: Biocon Sdn Bhd, a subsidiary of Biocon Limited has announced that it has received the Establishment Inspection Report (EIR) from the U.S....
Novo Nordisk Tresiba shows lower risk of hypo in adults with Type 2 Diabetes Medical Dialogues Bureau21 Sept 2019 9:30 AM IST"We are delighted that the findings of the CONCLUDE trial support what we have seen previously across the Tresiba clinical development programme,"...
Biocon, Mylan get European Commission approval to market biosimilar insulin glargine Ruby Khatun Khatun30 March 2018 10:30 AM ISTNew Delhi: Biotechnology major Biocon and Mylan said their co-developed biosimilar insulin glargine has received marketing authorization approval from...
Biocon, Mylan Present Clinical Data on Insulin Glargine at American Diabetes Associations 77th Scientific Sessions Ruby Khatun Khatun12 Jun 2017 11:29 AM ISTMylan N.V. and Biocon Ltd. announced the presentation of new data from the insulin glargine clinical program, including the INSTRIDE studies at the...
